219 related articles for article (PubMed ID: 37086849)
1. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
García-Cadenas I; Redondo S; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Oñate G; López J; Caballero AC; Miqueleiz S; Arguello-Tomas M; Briones J; Sierra J; Martino R
Transplant Cell Ther; 2023 Jul; 29(7):473.e1-473.e6. PubMed ID: 37086849
[TBL] [Abstract][Full Text] [Related]
2. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
3. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
5. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
7. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
[TBL] [Abstract][Full Text] [Related]
11. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Salas MQ; Pedraza A; Charry P; Suárez-Lledó M; Rodríguez-Lobato LG; Brusosa M; Solano MT; Serrahima A; Nomdedeu M; Cid J; Lozano M; Arcarons J; de Llobet N; Rosiñol L; Esteve J; Urbano-Ispizua Á; Carreras E; Fernández-Avilés F; Rovira M; Martinez C
Transplant Cell Ther; 2024 Feb; 30(2):213.e1-213.e12. PubMed ID: 38042256
[TBL] [Abstract][Full Text] [Related]
12. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
17. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
[TBL] [Abstract][Full Text] [Related]
20. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
